These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 25390135)

  • 1. Perspective: we need a global solution.
    Odame I
    Nature; 2014 Nov; 515(7526):S10. PubMed ID: 25390135
    [No Abstract]   [Full Text] [Related]  

  • 2. Sickle cell -- point, counterpoint.
    N Engl J Med; 1973 Aug; 289(6):323-4. PubMed ID: 4718041
    [No Abstract]   [Full Text] [Related]  

  • 3. Closing the Equity Gap: Early Intervention in Sickle Cell Disease.
    Williams AR; Archer NM
    Pediatrics; 2024 Jul; 154(1):. PubMed ID: 38836305
    [No Abstract]   [Full Text] [Related]  

  • 4. The changing face of international medicine.
    Coltart C
    Clin Med (Lond); 2012 Oct; 12(5):405-6. PubMed ID: 23101136
    [No Abstract]   [Full Text] [Related]  

  • 5. Q&A: healthy progress.
    Serjeant G; Mallapaty S
    Nature; 2014 Nov; 515(7526):S6-7. PubMed ID: 25390144
    [No Abstract]   [Full Text] [Related]  

  • 6. Perspective: thinking beyond survival.
    DeBaun MR
    Nature; 2014 Nov; 515(7526):S16. PubMed ID: 25390138
    [No Abstract]   [Full Text] [Related]  

  • 7. Barriers and facilitators to community acceptability of integrating point-of-care testing to screen for sickle cell disease in children in primary healthcare settings in rural Upper East Region of Northern Ghana.
    Chatio ST; Duah E; Ababio LO; Lister N; Egbujo O; Marfo K; Aborigo R; Ansah P; Odame I
    PLoS One; 2024; 19(5):e0303520. PubMed ID: 38768171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community health workers in India should be trained to offer genetic counselling for rare diseases.
    Patel D; Kumar R
    Nat Med; 2024 Feb; 30(2):319. PubMed ID: 38200260
    [No Abstract]   [Full Text] [Related]  

  • 9. Bridging the Access Gap for Comprehensive Sickle Cell Disease Management Across Sub-Saharan Africa: Learnings for Other Global Health Interventions?
    Hegemann L; Narasimhan V; Marfo K; Kuma-Aboagye P; Ofori-Acquah S; Odame I
    Ann Glob Health; 2023; 89(1):76. PubMed ID: 38025926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence Lifetime Measurement of Prefibrillar Sickle Hemoglobin Oligomers as a Platform for Drug Discovery in Sickle Cell Disease.
    Vunnam N; Hansen S; Williams DC; Been MO; Lo CH; Pandey AK; Paulson CN; Rohde JA; Thomas DD; Sachs JN; Wood DK
    Biomacromolecules; 2022 Sep; 23(9):3822-3830. PubMed ID: 35944154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases.
    Alabi OJ; Adegboyega FN; Olawoyin DS; Babatunde OA
    Heliyon; 2022 Jun; 8(6):e09630. PubMed ID: 35677416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective case study of successful translational research: Gazelle Hb variant point-of-care diagnostic device for sickle cell disease.
    Qua K; Swiatkowski SM; Gurkan UA; Pelfrey CM
    J Clin Transl Sci; 2021; 5(1):e207. PubMed ID: 35047218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menstrual characteristics of sickle cell disease patients seen at a tertiary institution in North Western Nigeria.
    Mohammed-Durosinlorun A; Bello-Manga H; Adze J; Ijei IP; Stephen B
    Ann Afr Med; 2021; 20(4):255-264. PubMed ID: 34893562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 gene editing for curing sickle cell disease.
    Park SH; Bao G
    Transfus Apher Sci; 2021 Feb; 60(1):103060. PubMed ID: 33455878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.
    Oluwole EO; Adeyemo TA; Osanyin GE; Odukoya OO; Kanki PJ; Afolabi BB
    PLoS One; 2020; 15(12):e0242861. PubMed ID: 33270733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paper-based microchip electrophoresis for point-of-care hemoglobin testing.
    Hasan MN; Fraiwan A; An R; Alapan Y; Ung R; Akkus A; Xu JZ; Rezac AJ; Kocmich NJ; Creary MS; Oginni T; Olanipekun GM; Hassan-Hanga F; Jibir BW; Gambo S; Verma AK; Bharti PK; Riolueang S; Ngimhung T; Suksangpleng T; Thota P; Werner G; Shanmugam R; Das A; Viprakasit V; Piccone CM; Little JA; Obaro SK; Gurkan UA
    Analyst; 2020 Apr; 145(7):2525-2542. PubMed ID: 32123889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
    Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
    Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
    Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
    Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Paper-Based Test for Screening Newborns for Sickle Cell Disease.
    Piety NZ; George A; Serrano S; Lanzi MR; Patel PR; Noli MP; Kahan S; Nirenberg D; Camanda JF; Airewele G; Shevkoplyas SS
    Sci Rep; 2017 Apr; 7():45488. PubMed ID: 28367971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging point-of-care technologies for sickle cell disease screening and monitoring.
    Alapan Y; Fraiwan A; Kucukal E; Hasan MN; Ung R; Kim M; Odame I; Little JA; Gurkan UA
    Expert Rev Med Devices; 2016 Dec; 13(12):1073-1093. PubMed ID: 27785945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.